Literature DB >> 11741266

Time- and concentration-dependent penetration of doxorubicin in prostate tumors.

J H Zheng1, C T Chen, J L Au, M G Wientjes.   

Abstract

The penetration of paclitaxel into multilayered solid tumors is time- and concentration-dependent, a result of the drug-induced apoptosis and changes in tissue composition. This study evaluates whether this tissue penetration property applies to other highly protein-bound drugs capable of inducing apoptosis. The penetration of doxorubicin was studied in histocultures of prostate xenograft tumors and tumor specimens obtained from patients who underwent radical prostatectomy. The kinetics of drug uptake and efflux in whole tumor histocultures were studied by analyzing the average tumor drug concentration using high-pressure liquid chromatography. Spatial drug distribution in tumors and the drug concentration gradient across the tumors were studied using fluorescence microscopy. The results indicate that drug penetration was limited to the periphery for 12 hours in patient tumors and to 24 hours in the more densely packed xenograft tumors. Subsequently, the rate of drug penetration to the deeper tumor tissue increased abruptly in tumors treated with higher drug concentrations capable of inducing apoptosis (i.e., = 5 microm), but not in tumors treated with lower concentrations. These findings indicate a time- and concentration-dependent penetration of doxorubicin in solid tumors, similar to that of paclitaxel. We conclude that doxorubicin penetration in solid tumors is time- and concentration-dependent and is enhanced by drug-induced cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741266      PMCID: PMC2779556          DOI: 10.1208/ps030215

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  35 in total

Review 1.  Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor.

Authors:  L A Kunz-Schughart
Journal:  Cell Biol Int       Date:  1999       Impact factor: 3.612

2.  Bladder tissue pharmacokinetics of intravesical taxol.

Authors:  D Song; M G Wientjes; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 3.  Intraperitoneal therapy of ovarian cancer.

Authors:  M Markman
Journal:  Semin Oncol       Date:  1998-06       Impact factor: 4.929

4.  Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies.

Authors:  O Nativ; M Aronson; O Medalia; T Moldavsky; E Sabo; I Ringel; V Kravtsov
Journal:  Int J Cancer       Date:  1997-01-27       Impact factor: 7.396

5.  Permeability of interstitial space of muscle (rat diaphragm) to solutes of different molecular weights.

Authors:  J S Schultz; W Armstrong
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

6.  Interstitial diffusion of macromolecules in the rat mesentery.

Authors:  J R Fox; H Wayland
Journal:  Microvasc Res       Date:  1979-09       Impact factor: 3.514

7.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

Authors:  M Nagabhushan; C M Miller; T P Pretlow; J M Giaconia; N L Edgehouse; S Schwartz; H J Kung; R W de Vere White; P H Gumerlock; M I Resnick; S B Amini; T G Pretlow
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

8.  Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.

Authors:  S H Jang; M G Wientjes; J L Au
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

9.  Oncotic pressure in solid tumors is elevated.

Authors:  M Stohrer; Y Boucher; M Stangassinger; R K Jain
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

Review 10.  Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?

Authors:  M Markman; P Francis; E Rowinsky; W Hoskins
Journal:  Semin Oncol       Date:  1995-06       Impact factor: 4.929

View more
  25 in total

Review 1.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Authors:  Jie Wang; Ze Lu; Yue Gao; M Guillaume Wientjes; Jessie L-S Au
Journal:  Nanomedicine (Lond)       Date:  2011-11       Impact factor: 5.307

2.  Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.

Authors:  Jie Wang; Ze Lu; Junfeng Wang; Minjian Cui; Bertrand Z Yeung; David J Cole; M Guillaume Wientjes; Jessie L-S Au
Journal:  J Control Release       Date:  2015-08-10       Impact factor: 9.776

3.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 4.  Extracellularly activatable nanocarriers for drug delivery to tumors.

Authors:  Sara A Abouelmagd; Hyesun Hyun; Yoon Yeo
Journal:  Expert Opin Drug Deliv       Date:  2014-06-20       Impact factor: 6.648

5.  Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.

Authors:  Jennifer A MacDiarmid; Nancy B Amaro-Mugridge; Jocelyn Madrid-Weiss; Ilya Sedliarou; Stefanie Wetzel; Kartini Kochar; Vatsala N Brahmbhatt; Leo Phillips; Scott T Pattison; Carlotta Petti; Bruce Stillman; Robert M Graham; Himanshu Brahmbhatt
Journal:  Nat Biotechnol       Date:  2009-06-28       Impact factor: 54.908

6.  Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.

Authors:  Federico Perche; Niravkumar R Patel; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-09-10       Impact factor: 9.776

7.  High-Content Screening Comparison of Cancer Drug Accumulation and Distribution in Two-Dimensional and Three-Dimensional Culture Models of Head and Neck Cancer.

Authors:  Feng Shan; David A Close; Daniel P Camarco; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2017-12-07       Impact factor: 1.738

8.  Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.

Authors:  Shun-Lai Li; Chia-Hsin Huang; Chih-Chan Lin; Zih-Ning Huang; Jyh-Haur Chern; Hsiao-Yin Lien; Yong-Yi Wu; Chia-Hui Cheng; Chia-Yu Chang; Jiunn-Jye Chuu
Journal:  Invest New Drugs       Date:  2009-12-05       Impact factor: 3.850

9.  Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.

Authors:  Ze Lu; Max Tsai; Dan Lu; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  J Pharmacol Exp Ther       Date:  2008-09-09       Impact factor: 4.030

10.  Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.

Authors:  John P Sinek; Sandeep Sanga; Xiaoming Zheng; Hermann B Frieboes; Mauro Ferrari; Vittorio Cristini
Journal:  J Math Biol       Date:  2008-09-10       Impact factor: 2.259

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.